| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) |
|
Medicine details |
|
| Medicine name | abatacept (Orencia®) |
| Formulation | subcutaneous injection |
| Reference number | 933 |
| Indication | Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/08/2017 |
| NICE guidance | TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) |